| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to Referees
|
|
|
|
16 |
6 |
p. 697-700
|
artikel
|
| 2 |
An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer
|
Lu, Yen-Shen
|
|
|
16 |
6 |
p. 701-741
|
artikel
|
| 3 |
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and Outcomes
|
Chouaid, Christos
|
|
|
16 |
6 |
p. 801-811
|
artikel
|
| 4 |
Association of Tumor Mutational Burden and Immune Gene Expression with Response to PD-1 Blockade by Sasanlimab Across Tumor Types and Routes of Administration
|
Hu-Lieskovan, Siwen
|
|
|
16 |
6 |
p. 773-787
|
artikel
|
| 5 |
Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study
|
Hawkes, Eliza A.
|
|
|
16 |
6 |
p. 761-771
|
artikel
|
| 6 |
Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
|
Frampton, James E.
|
|
|
16 |
6 |
p. 867
|
artikel
|
| 7 |
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
|
Lamb, Yvette N.
|
|
|
16 |
6 |
p. 869
|
artikel
|
| 8 |
Correction to: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice
|
Brufsky, Adam
|
|
|
16 |
6 |
p. 865
|
artikel
|
| 9 |
Durvalumab: A Review in Extensive-Stage SCLC
|
Al-Salama, Zaina T.
|
|
|
16 |
6 |
p. 857-864
|
artikel
|
| 10 |
Immune Checkpoint Inhibitors for Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis
|
Mehta, Neil K.
|
|
|
16 |
6 |
p. 743-752
|
artikel
|
| 11 |
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
|
Castagnetti, Fausto
|
|
|
16 |
6 |
p. 823-838
|
artikel
|
| 12 |
Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
|
Lee, Arnold
|
|
|
16 |
6 |
p. 839-845
|
artikel
|
| 13 |
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer
|
Paik, Julia
|
|
|
16 |
6 |
p. 847-856
|
artikel
|
| 14 |
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
|
Tsuji, Akihito
|
|
|
16 |
6 |
p. 753-760
|
artikel
|
| 15 |
Retrospective Chart Review of Dabrafenib Plus Trametinib in Patients with Metastatic BRAF V600-Mutant Melanoma Treated in the Individual Patient Program (DESCRIBE Italy)
|
Aglietta, Massimo
|
|
|
16 |
6 |
p. 789-799
|
artikel
|
| 16 |
Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy
|
Sheng, Iris Y.
|
|
|
16 |
6 |
p. 813-821
|
artikel
|
Tijdschrift beschrijving